Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

An oral drug delivery system using composite nanomaterials as a carrier

A technology of composite nanomaterials and drug delivery systems, applied in the oral Helicobacter pylori subunit vaccine, HP55/PBCA nanoparticle preparation field, can solve the problem of improving the bioavailability of oral protein drugs and resistance to gastrointestinal proteases Hydrolysis is weak and other problems, to achieve the effect of enhancing local mucosal immunity, preventing and treating Helicobacter pylori infection, and the preparation method is simple

Active Publication Date: 2021-07-27
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prior art has studied acid-resistant HP55 / PLGA nanoparticles for delivery of Helicobacter pylori vaccine, (document TAN ZL , LIU W , LIU H , et al . Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55 / PLGA nanoparticles promote immune protection [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 111: 33-43.) It has been demonstrated that HP55 can resist the acidic environment of the stomach, but because PLGA itself is polymerized by lactic acid and glycolic acid through ester bonds, it is resistant to gastric The hydrolysis of intestinal protease is weak, and the bioavailability of oral protein drugs still needs to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An oral drug delivery system using composite nanomaterials as a carrier
  • An oral drug delivery system using composite nanomaterials as a carrier
  • An oral drug delivery system using composite nanomaterials as a carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Preparation of PBCA-CCF NPs and HP55 / PBCA-CCF NPs.

[0047] (1) Weigh the prescribed amount of 25 mg HP55 and absorb 50 μL of BCA monomer, dissolve in 5 mL of acetone, and prepare the drug-loaded organic phase for use.

[0048] (2) Weigh 50 mg of poloxamer 188 and dissolve it in 5 mL of the antigenic protein solution separated and purified in our laboratory to make an aqueous phase solution.

[0049] (3) Add the organic phase prepared in step (1) dropwise into the aqueous phase prepared in step (2) with a syringe under 350rpm magnetic stirring at 4°C, and continue stirring for 4.5 hours after the addition is complete , the acetone was evaporated and removed, and finally filtered with a 0.45 μm filter membrane to obtain a milky white stable and uniform HP55 / PBCA nanoparticle suspension.

[0050] (4) Put the nanoparticle suspension into a suitable container and pre-freeze at -20°C for 12 hours, then freeze-dry and store.

[0051] Using the same method and the...

Embodiment 2

[0054] Example 2: PBCA-CCF NPs and HP55 / PBCA-CCF NPs vaccines induce a high level of systemic immune response.

[0055] (1) Grouping scheme of SPF BALB / c mice: (A) NC group: Mice were orally administered a suspension of 500 μL PBS and aluminum hydroxide adjuvant. (B) HP55 / PBCA-group: Mice were orally administered composite HP55 / PBCA nanoparticles without antigen encapsulation. (C) HP55 / PBCA-CCF group: Mice were orally administered composite HP55 / PBCA nanoparticles encapsulated with 100 μg CCF. (D) PBCA-CCF group: Mice were orally administered ordinary PBCA nanoparticles encapsulated with 100 μg CCF. (E) Alum-CCF group: Mice were orally administered a suspension of 100 μg CCF and aluminum hydroxide adjuvant.

[0056] (2) Mice immunization and challenge program: according to Figure 4 , orally immunized 4 times by intragastric administration, with an interval of 7 days each time, and challenged the immunized mice once two weeks later: intragastric administration of Hp suspens...

Embodiment 3

[0062] Example 3: PBCA-CCF NPs and HP55 / PBCA-CCF NPs vaccines induce secretory IgA.

[0063] H. pylori can selectively colonize the gastric mucosa and, if not cleared, will cause chronic inflammation. Secretory IgA is a marker of local mucosal immune response, and the detection of gastric sIgA has guiding significance for judging the preventive and therapeutic effect of vaccines.

[0064] Gastric mucosa sample collection protocol: according to Figure 4 , 4 weeks after the last immunization, the mice were sacrificed by intraperitoneal injection of excess ether, the stomach of the mouse was taken, and the stomach was cut longitudinally along the greater curvature of the stomach, and 0.1 g of gastric tissue was taken, added to 500 μL of PBS, and fully homogenized with a homogenizer , centrifuged at 3000rpm for 30min, and collected the supernatant.

[0065] In order to study the level of gastric mucosal immune response, we used ELISA method to detect the level of sIgA in the st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
polydispersity indexaaaaaaaaaa
Login to View More

Abstract

The invention discloses an oral drug delivery system using composite nanomaterials as carriers. The composite nanomaterials HP55 and PBCA are used as shells to coat drug solutions to form nanoparticles. The method adopts the biodegradable and good biocompatibility composite nanometer material as the carrier of the oral medicine, which can improve the bioavailability of the oral medicine. In the field of biomedicine, the nanoparticle can be used for oral delivery of Helicobacter pylori subunit vaccines, which can play a huge role in preventing and treating diseases related to Helicobacter pylori infection.

Description

technical field [0001] The invention belongs to the field of new dosage forms of pharmaceutical preparations, and relates to an oral drug delivery system with a composite nanomaterial as a carrier and its application, specifically the preparation of a HP55 / PBCA nanoparticle and its application in an oral Helicobacter pylori subunit vaccine application. Background technique [0002] Oral vaccines (especially new vaccines such as DNA vaccines and recombinant protein peptide vaccines) will be directly affected by the pH environment and various enzyme systems in the gastrointestinal tract, resulting in the degradation and inactivation of active vaccines, and their absorption efficiency and bioavailability are usually the same. Low, the antigen concentration at the target inoculation site is insufficient, and it is generally difficult to elicit an effective immune response. Therefore, special oral vaccine delivery systems are required. At present, the microparticle delivery car...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/51A61K47/38A61K47/32A61K39/02A61P31/04
CPCA61K9/5138A61K9/5161A61K39/0208A61K2039/542A61K2039/70
Inventor 奚涛邢莹莹刘海刘巍谭周林
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com